Candel Therapeutics, Inc. (CADL)
CADL moved a median of -0.16% 30 minutes after news, and -0.34% by the close. How CADL actually reacts to news — the realized, point-in-time move the market made, measured across 354 labeled events over the last three years with zero look-ahead.
CADL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.11% | 41% | 346 |
| 30-min | -0.16% | 43% | 352 |
| 60-min | -0.33% | 45% | 353 |
| to close | -0.34% | 45% | 349 |
| Middle 50% of CADL reactions | -2.12% to +1.17% |
|---|---|
| Median reaction (30-min) | -0.16% |
| Measured reactions | 354 |
Half of all Candel Therapeutics, Inc. news events land between -2.12% and +1.17% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CADL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | +0.60% | 82% | -1.64% |
| Coverage initiations | 24 | +1.29% | 71% | +0.54% |
| Rating reiterations | 27 | +0.42% | 52% | +0.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CADL ranks against every other measured name →
That’s how CADL usually reacts — get an email when it moves on news →Email me when CADL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CADL's baseline. Nothing else.
Recent CADL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Candel Therapeutics to Present at the SITC 2026 Annual Meeting | Press release | GlobeNewswire | -0.58% | -1.07% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.58% | -1.07% | |
| Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Resp | Press release | GlobeNewswire | -2.15% | -5.22% | |
| Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer | Press release | GlobeNewswire | +0.00% | -5.26% | |
| Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 | Press release | GlobeNewswire | +0.00% | -5.26% | |
| Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | Press release | GlobeNewswire | -0.50% | -5.97% | |
| Form 8-K Candel Therapeutics, For: Sep 06 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -5.97% | |
| Form 8-K Candel Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -5.97% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.84% | +2.72% | |
| Candel Therapeutics to Present at September Investor Conferences | Press release | GlobeNewswire | -0.96% | -2.35% | |
| Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -0.92% | +8.76% | |
| Form 10-Q Candel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.92% | +8.76% | |
| Form 8-K Candel Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | +8.76% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.98% | +3.55% | |
| Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 | Press release | GlobeNewswire | -3.51% | +1.00% | |
| Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston | Press release | GlobeNewswire | -0.31% | -4.18% | |
| Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.60% | -1.30% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.25% | -1.40% | |
| Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Press release | GlobeNewswire | +0.86% | -1.34% | |
| Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer | Press release | GlobeNewswire | -0.27% | +2.49% | |
| Form 8-K Candel Therapeutics, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +2.49% | |
| Form 8-K Candel Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -0.87% | |
| Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer | Press release | GlobeNewswire | -2.35% | -1.17% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.35% | -1.17% | |
| Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting | Press release | GlobeNewswire | -5.22% | -10.13% | |
| Form 8-K Candel Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -5.22% | -10.13% | |
| Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -9.34% | -2.62% | |
| Form 10-Q Candel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.34% | -2.62% | |
| Form 8-K Candel Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -9.34% | -2.62% | |
| Candel Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.75% | +3.35% | |
| Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Press release | GlobeNewswire | +3.35% | +14.61% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.35% | +14.61% | |
| Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer | Press release | GlobeNewswire | +1.85% | -0.48% | |
| Form ARS Candel Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.08% | +0.00% | |
| Form DEF 14A Candel Therapeutics, For: Jun 23 | SEC filing · Form DEF | SEC EDGAR | +0.08% | +0.00% | |
| Form DEFA14A Candel Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.08% | +0.00% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.00% | +0.20% | |
| Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Press release | GlobeNewswire | +2.00% | +3.19% | |
| Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | +0.20% | -0.60% | |
| Form 10-K Candel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.20% | -0.60% | |
| Form 8-K Candel Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | -0.60% | |
| Form S-8 Candel Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.20% | -0.60% | |
| Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Press release | GlobeNewswire | +4.38% | +7.10% | |
| Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.50% | -1.80% | |
| Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston | Press release | GlobeNewswire | -0.71% | +3.67% | |
| Form 8-K Candel Therapeutics, For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -1.58% | |
| Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer | Press release | GlobeNewswire | -1.08% | -6.33% | |
| Candel Therapeutics Announces Pricing of Public Offering | Press release | GlobeNewswire | -1.08% | -6.33% | |
| Candel Therapeutics Announces Proposed $100 Million Public Offering | Press release | GlobeNewswire | -1.08% | -6.33% | |
| Form 8-K Candel Therapeutics, For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | -6.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CADL section they belong to.
Where else CADL is measured.
CADL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Candel Therapeutics, Inc.'s median reaction calculated?
Every labeled CADL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 354 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of CADL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CADL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.